LOGIN  |  REGISTER
Compass Therapeutics

Modivcare to Present at the BofA Securities 2023 Health Care Conference

April 26, 2023 | Last Trade: US$3.21 0.52 -13.94

DENVER / Apr 26, 2023 / Business Wire / Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced that Heath Sampson, Modivcare’s President and Chief Executive Officer, is scheduled to participate in a fireside chat presentation at the BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10, 2023 at 3:00 p.m. (Pacific Daylight Time). Management will also host investor meetings throughout the day.

A link to the live webcast of the Company’s presentation can be found here or on Modivcare’s Investor Relations website at Modivcare Inc. - Investor Overview. A replay of the presentation will be available for 90 days following the date of the presentation.

About Modivcare

Modivcare Inc. (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their members. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page